Last updated on February 2018

Hypofractionation With Simultaneous Integrated Boost vs. Standard Fractionation in Early Breast Cancer


Brief description of study

Hypofractionation with simultaneous integrated boost has been investigated in a few trials and appears to be safe and feasible.

Investigators initiated this multicenter two-armed phase III prospective trial to analyse the non-inferiority of hypofractionation with simultaneous integrated boost in patients with early breast cancer in comparison to standard fractionation.

Detailed Study Description

Control Arm:

Conventionaly fractionated radiotherapy of the breast 28 1.8 Gy = 50.4 Gy followed by a tumor bed boost sequentially 5 to 8 2.0 Gy = 10.0 Gy to 16.0 Gy, total dose 60.4 Gy to 66.4 Gy.

or Conventionaly fractionated radiotherapy of the breast 28 1.8 Gy = 50.4 Gy with simultaneous integrated boost to the tumor bed, total dose 28 0.3 Gy or 0.45 Gy= 8.4 Gy or 12,6 Gy, total dose 58,8 Gy to 63.0 Gy.

or Hypofractionated radiotherapy of the breast 16 2.66 Gy = 42.56 Gy followed by a tumor bed boost sequentially 5 to 8 2.0 Gy = 10.0 Gy to 16.0 Gy, total dose 52.56 Gy to 58.56 Gy.

Experimental Arm:

Hypofractionated radiotherapy of the breast 16 2.50 Gy with simultaneous integrated boost to the tumor bed, total dose within the boost volume 16 3.00 Gy.

Clinical Study Identifier: NCT02474641

Find a site near you

Start Over